Fortune January 20, 2025
Carolyn Barber

Drugs like Ozempic and Wegovy were already off to fast starts because of their ability to help treat Type 2 diabetes and improve weight loss for millions of Americans. But a new study suggests that those may represent only a small sample of the potential uses of the drugs.

The study, led by researchers at the Veterans Affairs St. Louis Health Care System, found that use of these GLP-1s, as they are classified, was associated with reduced risks of a number of health problems, including substance abuse disorders, suicidal ideation, schizophrenia and other psychotic disorders. Risk reduction was also found for neurocognitive disorders like Alzheimer’s and dementia, along with infections, liver cancer, and even life-threatening clotting disorders, like blood...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article